NeuBase Therapeutics, Inc. Stock price

Equities

NBSE

US64132K2015

Biotechnology & Medical Research

Delayed Nasdaq 03:46:16 2024-03-28 pm EDT 5-day change 1st Jan Change
0.4444 USD +2.23% Intraday chart for NeuBase Therapeutics, Inc. -56.85% -39.95%
Sales 2023 * - Sales 2024 * - Capitalization 1.63M
Net income 2023 * -12M Net income 2024 * - EV / Sales 2023 * -
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-0.06 x
P/E ratio 2024 *
-
Employees 37
Yield 2023 *
-
Yield 2024 *
-
Free-Float 86.56%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on NeuBase Therapeutics, Inc.

1 day+2.23%
1 week-56.85%
Current month-48.33%
1 month-49.22%
3 months-37.50%
6 months-52.72%
Current year-39.95%
More quotes
1 week
0.40
Extreme 0.403
1.05
1 month
0.40
Extreme 0.403
1.15
Current year
0.40
Extreme 0.403
1.15
1 year
0.40
Extreme 0.403
5.40
3 years
0.40
Extreme 0.403
153.40
5 years
0.40
Extreme 0.403
257.80
10 years
0.40
Extreme 0.403
257.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 22-01-09
Corporate Officer/Principal - -
Corporate Officer/Principal - 21-10-31
Members of the board TitleAgeSince
Chairman 56 19-07-11
Director/Board Member 63 19-07-11
Director/Board Member 79 19-07-11
More insiders
Date Price Change Volume
24-03-28 0.4444 +2.23% 272 857
24-03-27 0.4347 -9.21% 656,232
24-03-26 0.4788 -52.12% 1,382,295
24-03-25 1 -2.91% 721,260
24-03-22 1.03 0.00% 33,231

Delayed Quote Nasdaq, March 28, 2024 at 03:46 pm EDT

More quotes
NeuBase Therapeutics, Inc. is a preclinical-stage biotechnology company. It is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Company’s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. It uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntington’s disease (HD), and oncology and in gene editing applications. It also focused on identifying and evaluating multiple indications for potential development.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
  1. Stock
  2. Equities
  3. Stock NeuBase Therapeutics, Inc. - Nasdaq